{"title":"蛋白转化酶枯草杆菌素-可辛9型(pcsk9)抑制剂的高脂血症管理","authors":"A. Kinsara","doi":"10.23937/2378-2951/1410146","DOIUrl":null,"url":null,"abstract":"Significant improvement in control of cardiovascular risk factors has been driven by performance measurement that focused on attainment of specific risk factor thresholds for blood glucose, lipids and blood pressure. Diet, statin and ezetimibe have reasonably controlled hyperlipidemia. However the discovery of proprotein convertase subtilisin-kexin type 9 inhibitors has given new hope of reaching the target lipid profile especially in the high-risk group and familial hypercholesterolemia. Herewith we reviewed the current data and explore the cardiovascular prevention effect of this group.","PeriodicalId":112011,"journal":{"name":"International Journal of Clinical Cardiology","volume":"62 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hyperlipidemia Management in Proprotein Convertase Subtilisin- Kexin Type 9 (PCSK 9) Inhibitors Era\",\"authors\":\"A. Kinsara\",\"doi\":\"10.23937/2378-2951/1410146\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Significant improvement in control of cardiovascular risk factors has been driven by performance measurement that focused on attainment of specific risk factor thresholds for blood glucose, lipids and blood pressure. Diet, statin and ezetimibe have reasonably controlled hyperlipidemia. However the discovery of proprotein convertase subtilisin-kexin type 9 inhibitors has given new hope of reaching the target lipid profile especially in the high-risk group and familial hypercholesterolemia. Herewith we reviewed the current data and explore the cardiovascular prevention effect of this group.\",\"PeriodicalId\":112011,\"journal\":{\"name\":\"International Journal of Clinical Cardiology\",\"volume\":\"62 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical Cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.23937/2378-2951/1410146\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23937/2378-2951/1410146","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Hyperlipidemia Management in Proprotein Convertase Subtilisin- Kexin Type 9 (PCSK 9) Inhibitors Era
Significant improvement in control of cardiovascular risk factors has been driven by performance measurement that focused on attainment of specific risk factor thresholds for blood glucose, lipids and blood pressure. Diet, statin and ezetimibe have reasonably controlled hyperlipidemia. However the discovery of proprotein convertase subtilisin-kexin type 9 inhibitors has given new hope of reaching the target lipid profile especially in the high-risk group and familial hypercholesterolemia. Herewith we reviewed the current data and explore the cardiovascular prevention effect of this group.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
